Author

K. Drenner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

J. Trent· 2 shared A. Nazareno· 1 shared A. Weston· 1 shared B. Weissman· 1 shared D. P. Carbone· 1 shared G. Lorch· 1 shared H. Vankayalapati· 1 shared J. D. Lang· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Trent

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

R. Soldi, T. Ghosh Halder, A. Weston, T. Thode, K. Drenner, R. Lewis, M. R. Kaadige, S. Srivastava, S. Daniel Ampanattu, R. Rodriguez del Villar, J. D. Lang, H. Vankayalapati, B. Weissman, J. Trent, W. Hendricks, S. Sharma

This study shows that the LSD1 inhibitor SP-2577 enhances anti-tumor immunity and PD-L1 expression in SWI/SNF-mutated ovarian cancer models.

bioRxiv · Jan 10, 2020Cancer Biology

Identification of frequent activating HER2 mutations in primary canine pulmonary adenocarcinoma

G. Lorch, K. Sivaprakasam, V. Zismann, N. Perdigones, T. Contente-Cuomo, A. Nazareno, S. Facista, S. Wong, K. Drenner, W. S. Liang, J. M. Amann, S. L. Sinicropi-Yao, M. J. Koenig, K. La Perle, T. G. Whitsett, , W. P. D. Hendricks

This study identifies HER2 mutations in canine pulmonary adenocarcinomas, finding V659E mutations in 38% of cases and their association with drug sensitivity.

bioRxiv · Feb 25, 2019 · PreprintCancer Biology